Ad
related to: alk inhibitors for cancer- Once-daily Dosing
Learn more about efficacy &
convenient dosing of this treatment
- ALK+ mNSCLC Support
Build a treatment plan to
help patients reach their goals.
- Once-daily Dosing
Search results
Results from the WOW.Com Content Network
ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. [1] They fall under the category of tyrosine kinase inhibitors , which work by inhibiting proteins involved in the abnormal growth of tumour cells.
Brigatinib is an inhibitor of ALK [3] and mutated EGFR. [5]ALK was first identified as a chromosomal rearrangement in anaplastic large cell lymphoma (ALCL). Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL.
It restricts and constrains learning and long-term memory [27] [55] [44] and small-molecule inhibitors of the ALK receptor can improve learning, [27] long-term memory, [55] and extend healthy lifespan. [56] ALK is also a candidate thinness gene, as its genetic deletion leads to resistance to diet- and leptin-mutation-induced obesity. [57] [N 1]
Ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor primarily used for the treatment of ALK positive metastatic NSCLC. [8] [9] Previously, it was only indicated for patients who had developed resistant to crizotinib, another ALK inhibitor, but has since had its usage expanded to serve as a primary option for metastatic NSCLC.
Ensartinib, sold under the brand name Ensacove, is an anti-cancer medication used for the treatment of non-small cell lung cancer. [1] Ensartinib is an Anaplastic lymphoma kinase (ALK) inhibitor used as the salt ensartinib hydrochloride. [1] It is taken by mouth. [1]
Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2 and EGFR: Medullary thyroid cancer. Diarrhoea, hypertension, QT interval prolongation, depression, electrolyte anomalies, hypothyroidism and GI perforation (uncommon). 2.3 mTOR inhibitors: Everolimus: PO: mTOR inhibitor.
In thoracic cancer, we achieved 31% operational growth this quarter with LORBRENA, a treatment for adult with ALK-positive metastatic noncell lung cancer. ... On your CDK4 inhibitor, you guided to ...
Alectinib (INN [8]), sold under the brand name Alecensa, is an anticancer medication that is used to treat non-small-cell lung cancer (NSCLC). [6] [7] It blocks the activity of anaplastic lymphoma kinase (ALK). [9] [10] It is taken by mouth. [6] It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
Ad
related to: alk inhibitors for cancer